GD
IOVA icon

Grandfield & Dodd’s Iovance Biotherapeutics IOVA Stock Holding History

Grandfield & Dodd’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$211K Sell
60,180
-5,750
-9% -$18.4K 0.01% 200
2025
Q4 		$180K Sell
65,930
-11,895
-15% -$27.5K 0.01% 206
2025
Q3 		$169K Sell
77,825
-13,250
-15% -$31.3K 0.01% 210
2025
Q2 		$157K Buy
91,075
+100
+0.1% +$249 0.01% 211
2025
Q1 		$303K Buy
90,975
+35,260
+63% +$182K 0.02% 169
2024
Q4 		$412K Buy
55,715
+25,645
+85% +$238K 0.03% 151
2024
Q3 		$282K Buy
+30,070
New +$285K 0.02% 182

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Grandfield & Dodd's IOVA Position: Q1 2026 in Review

Grandfield & Dodd reduced its Iovance Biotherapeutics (IOVA) stake by 8.7% in Q1 2026, selling an estimated $18.4K and leaving 60,180 shares worth $211K. The position accounts for 0.01% of the portfolio, ranked #200.

Grandfield & Dodd first reported a position in IOVA in Q3 2024 and has held it in 7 quarters since. The position peaked at $412K in Q4 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Grandfield & Dodd held 60,180 shares of Iovance Biotherapeutics worth $211K as of Q1 2026.
  • Grandfield & Dodd sold 5,750 Iovance Biotherapeutics shares in Q1 2026, an estimated $18.4K.
  • Iovance Biotherapeutics made up 0.01% of Grandfield & Dodd's portfolio in Q1 2026, its #200 holding.
  • Grandfield & Dodd first reported a position in Iovance Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Grandfield & Dodd's Iovance Biotherapeutics position peaked at $412K in Q4 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.